

Neurizon Invites Investors to Melbourne Briefing

Highlights:

- Neurizon's investor engagement series continues, with the next in-person investor briefing in Melbourne on Wednesday, 29 July 2026
- Interim Executive Chairman, Sergio Duchini, will provide an update on recent advancements and upcoming milestones, followed by an interactive Q&A and networking session
- The briefing follows a period of strong clinical, operational and corporate momentum, with progress across the HEALEY ALS Platform Trial, long-term manufacturing readiness and a series of important upcoming development milestones

02 July 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to invite shareholders and interested investors to attend an in-person investor briefing in Melbourne on Wednesday, 29 July 2026. The briefing follows a period of significant progress across Neurizon's clinical development program, manufacturing strategy and corporate execution, as the Company advances NUZ-001 through the HEALEY ALS Platform Trial.

During the briefing, Interim Executive Chairman, Sergio Duchini will provide an update on the Company's recent clinical, operational and corporate achievements, including significant progress in the HEALEY ALS Platform Trial recruitment, recent manufacturing and supply milestones, and the strategic importance of the Company's long-term supply agreement with Elanco in supporting the long-term development pathway for NUZ-001. The presentation will also cover an overview of upcoming clinical, regulatory and operational milestones expected to shape the Company's next phase of development.

The formal presentation will be followed by an interactive Q&A session, providing attendees with the opportunity to engage directly with Neurizon's leadership team, gain deeper insights into the Company's strategy and upcoming milestones, and connect with members of the management team over drinks and canapés.

Interim Executive Chairman, Mr Sergio Duchini commented: "We are delighted to continue our investor engagement series with our upcoming Melbourne briefing, building on the strong interest seen at earlier sessions."

"With encouraging momentum in the HEALEY ALS Platform Trial, important operational achievements and several key milestones ahead, we believe this is an important opportunity for investors to hear firsthand about the Company's progress, strategic priorities and the next phase of development for NUZ-001."

"We warmly welcome both existing shareholders and prospective investors to join us, engage directly with our leadership team, ask questions and gain deeper insights into the opportunities and milestones ahead. We look forward to meeting members of the investment community in Melbourne and continuing these conversations over the coming months."

Event details

Date	Wednesday, 29 July, 2026
Time	5:00 – 7:00pm AEST
Location	Gilbert + Tobin meeting room Level 25/101 Collins Street, Melbourne
RSVP	By Wednesday, 22 July, 2026 irpr@irdepartment.com.au – please note in your email that you would like to attend the Neurizon Melbourne investor briefing event.

The Neurizon team looks forward to seeing all those investors who can join us at this event.

-ENDS-

This announcement has been authorised for release by the Interim Executive Chairman on behalf of the Board of Neurizon Therapeutics Limited.

For further information, please contact:

Marketing & Corporate Affairs

Lidija Damjanovic
Neurizon Therapeutics
Email: lidija@neurizon.com
Phone: +61 (0) 425 700 504

Investor Relations

Henry Jordan
Six Degrees Investor Relations
Email: henry.jordan@sdir.com.au
Phone: +61 (0) 431 271 538

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a late clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical program, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit <https://investorhub.neurizon.com>



Neurizon® is a registered trademark of Neurizon Therapeutics Limited